Harrow Health(US:HROW)2026-03-02 21:31Revenue and Sales - The company is focused on increasing revenues from ophthalmic products and optimizing pharmacy operations to enhance operating efficiencies[46] - Sales in the U.S. are significantly influenced by reimbursement availability from third-party payors, including Medicare and Medicaid[47] - The company is required to report average sales prices for certain drugs to Medicare, with new regulations effective in 2023 imposing penalties for non-compliance[49] - The Inflation Reduction Act of 2022 established a drug price negotiation program, which will cap prices for certain high Medicare spending drugs starting in 2026[50] - Medicaid rebates are based on pricing data reported to CMS, with the cap on rebates removed effective January 1, 2024, potentially increasing rebate liabilities[54] - All revenues for 2025, 2024, and 2023 were attributed to the U.S., with no international operations reported[82] Product Development and R&D - The company has over 50 issued and pending patent applications as of March 2, 2026, indicating a strong focus on intellectual property protection[63] - The company has a diverse patent portfolio, with key patents expiring between 2027 and 2039, covering various ophthalmic products[66] - In 2025, R&D expenses totaled $20,940,000, a significant increase from $12,230,000 in 2024 and $6,652,000 in 2023, reflecting a focus on ophthalmic products and drug candidate development[80] - The company recorded $8,450,000 in acquired-in-process R&D as part of the acquisition of Melt in November 2025[80] - The company is actively pursuing FDA approval for new product candidates through the NDA process, which may require additional studies and post-marketing reporting[68] Regulatory Compliance - The company operates under both Section 503A and Section 503B of the FDCA, which govern pharmacy compounding and outsourcing facilities, respectively[74] - The company is subject to rigorous federal and state regulations, including compliance with the Drug Quality and Security Act of 2013, which has increased the complexity of the regulatory environment[74] - The company has faced FDA inspections and has undertaken remediation and quality initiatives to ensure compliance with current good manufacturing practices (cGMP)[76] - The California Board of Pharmacy approved a settlement agreement that requires the company to surrender its 503B out-of-state outsourcing facility license by February 1, 2026[75] Employment and Talent Management - As of February 25, 2026, the company employed 373 individuals and plans to add more employees, particularly in sales and commercial activities, over the next 12 months[83] - The company recognizes the importance of attracting and retaining talent, supported by competitive compensation and benefits packages[86] Financial Position and Risk Management - As of December 31, 2025, a hypothetical 100 basis point movement in market interest rates would change the estimated fair value of the company's fixed-rate debt by approximately $2.5 million[331] - The company does not believe that reasonably likely changes in interest rates would have a material effect on its consolidated financial position, results of operations, or cash flows[332] - The company does not use derivative financial instruments, including interest rate swaps, to manage interest rate risk[333] - There is no material exposure to foreign currency exchange rate risk, commodity price risk, or other market risks[334] Reimbursement and Pricing - The company has received permanent product-specific J-codes for IHEEZO, TRIESENCE, BYOOVIZ, and OPUVIZ, facilitating reimbursement processes[52] - IHEEZO has been granted temporary pass-through reimbursement status effective in Q2 2023, expected to expire on March 31, 2026[53] - The company participates in the 340B drug pricing program, which requires charging covered entities no more than the 340B ceiling price for outpatient drugs[57]